Corbus reports Q2 net loss of $35M; cash $117.9M; FDA clearance for CRB-701 registrational study

Corbus Pharmaceuticals Holdings, Inc.

Net loss of $35.0M ($1.81 per share) vs $17.7M ($1.44) in Q2 2025; operating expenses rose to $36.2M including $10M milestone payment.
Cash and investments $117.9M as of June 30, 2026, expected to fund operations into 2028.
FDA cleared TEMPO-1 registrational study (n=250) of CRB-701 in 2L oropharyngeal cancer; enrollment to start September 2026.
CANYON-1 Phase 1b study of CRB-913 in obesity completed last patient visit; topline data expected September 2026.
Appointed new CMO (Dr. Leonardo Viana Nicacio), CBO (Nishant Saxena), and Board member (Brent Pfeiffenberger).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.